Abstract
The year 2017 will mark the 200th anniversary of the 1817 publication of James Parkinson’s monograph “An Essay on the Shaking Palsy.” In his monograph, Parkinson described six individuals suffering from a condition involving a bent posture, involuntary tremulous motion and weakened muscular action. Today, Parkinson’s disease (PD) in its various forms is recognized as the second most prevalent neurodegenerative disorder. It has an incidence rate of 1% for individuals age 65 and older and that rate increases to 5% for people past the age of 85.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Bibliography
Environmental Toxins
Betarbet, R., Canet-Aviles, R. M., Sherer, T. B., Mastroberardino, P. G., McLendon, C., Kim, J. H., et al. (2006). Intersecting pathways to neurodegeneration in Parkinson’s disease: Effects of the pesticide rotenone on DJ-1, α-synuclein, and the ubiquitin-proteasome system. Neurobiology of Disease, 22, 404–420.
Costello, S., Cockburn, M., Bronstein, J., Zhang, X., & Ritz, B. (2009). Parkinson’s disease and residential exposure to maneb and paraquat from agricultural applications in the Central Valley of California. American Journal of Epidemiology, 169, 919–926.
McCormack, A. L., Thiruchelvam, M., Manning-Bog, A. B., Thiffault, C., Langston, J. W., Cory-Slechta, D. A., et al. (2002). Environmental risk factors and Parkinson’s disease: Selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiology of Disease, 10, 119–127.
Tanner, C. M., Kamel, F., Ross, G. W., Hoppin, J. A., Goldman, S. M., Korell, M., et al. (2011). Rotenone, paraquat, and Parkinson’s disease. Environmental Health Perspectives, 119, 866–872.
Discovery of α-Synuclein and Its Connection to PD
Chartier-Harlin, M. C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., et al. (2004). α-Synuclein locus duplication as a cause of familial Parkinson’s disease. Lancet, 364, 1167–1169.
Maraganore, D. M., de Andrade, M., Elbaz, A., Farrer, M. J., Ionnidis, J. P., Krüger, R., et al. (2006). Collaborative analysis of α-synuclein gene promoter variability and Parkinson disease. JAMA, 296, 661–670.
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., et al. (1997). Mutation in the α-synuclein gene identified in families with Parkinson’s disease. Science, 276, 2045–2047.
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., et al. (2003). α-Synuclein triplication causes Parkinson’s disease. Science, 302, 841.
Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M., & Goedert, M. (1998). α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies. Proceedings of the National Academy of Sciences of the United States of America, 95, 6469–6473.
Spillantini, M. G., Schmidt, M. L., Lee, V. M. Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997). α-Synuclein in Lewy bodies. Nature, 388, 839–840.
Physiology of SNc Neurons
Matsuda, W., Furuta, T., Nakamura, K. C., Hioki, H., Fujiyama, F., Arai, R., et al. (2009). Single nigrostriatal dopaminergic neurons form widely spread and highly dense axonal arborizations in the neostriatum. The Journal of Neuroscience, 29, 444–453.
Puopolo, M., Ravoila, E., & Bean, B. P. (2007). Roles of subthreshold calcium current and sodium current in spontaneous firing of mouse midbrain dopamine neurons. The Journal of Neuroscience, 27, 645–656.
Surmeier, D. J., Guzman, J. N., & Sánchez-Padilla, J. (2010). Calcium, cellular aging, and selective neuronal vulnerability in Parkinson’s disease. Cell Calcium, 47, 175–182.
Dopaminergic Modulation of Synaptic Transmission
Kreitzer, A. C., & Malenka, R. C. (2008). Striatal plasticity and basal ganglia circuit function. Neuron, 60, 543–554.
Shen, W., Flajolet, M., Greengard, P., & Surmeier, D. J. (2008). Dichotomous dopaminergic control of striatal synaptic plasticity. Science, 321, 848–851.
Tritsch, N. X., & Sabatini, B. L. (2012). Dopamergic modulation of synaptic transmission in cortex and striatum. Neuron, 76, 33–50.
Biophysical Properties of α-Synuclein
Davidson, W. S., Jonas, A., Clayton, D. F., & George, J. M. (1998). Stabilization of α-synuclein secondary structure upon binding to synthetic membranes. The Journal of Biological Chemistry, 273, 9443–9449.
Eliezer, D., Kutluay, E., Bussell, R., Jr., & Browne, G. (2001). Conformational properties of α-synuclein in its free and lipid-associated states. Journal of Molecular Biology, 307, 1061–1073.
Ferreon, A. C. M., Gambin, Y., Lemke, E. A., & Deniz, A. A. (2009). Interplay of α-synuclein binding and conformational switching probed by single-molecule fluorescence. Proceedings of the National Academy of Sciences of the United States of America, 106, 5645–5650.
Fortin, D. L., Troyer, M. D., Nakamura, K., Kubo, S. I., Anthony, M. D., & Edwards, R. H. (2004). Lipid rafts mediate the synaptic localization of α-synuclein. The Journal of Neuroscience, 24, 6715–6723.
Jo, E., McLaurin, J. A., Yip, C. M., St. George-Hyslop, P., & Fraser, P. E. (2000). α-Synuclein membrane interactions and lipid specificity. The Journal of Biological Chemistry, 275, 34328–34334.
Middleton, E. R., & Rhoades, E. (2010). Effect of curvature and composition on α-synuclein binding to lipid vesicles. Biophysical Journal, 99, 2279–2288.
Solanki, A., Neupane, K., & Woodside, M. T. (2014). Single-molecule force spectroscopy of rapidly fluctuating, marginally stable structures in the intrinsically disordered protein α-synuclein. Physical Review Letters, 112, 158103.
Westphal, V., Rizzoli, S. O., Lauterbach, M. A., Kamin, D., Jahn, R., & Hell, S. W. (2008). Video-rate far-field optical nanoscopy dissects synaptic vesicle movement. Science, 320, 246–249.
Presynaptic Functions of α-Synuclein
Burré, J., Sharma, M., Tsetsenis, T., Buchman, V., Etherton, M. R., & Südhof, T. C. (2010). α-Synuclein promotes SNARE complex assembly in vivo and in vitro. Science, 329, 1663–1667.
Chandra, S., Gallardo, G., Fernánsez-Chacón, R., Schlüter, O. M., & Südhof, T. C. (2005). α-Synuclein cooperates with CSPα in preventing neurodegeneration. Cell, 123, 383–396.
Cooper, A. A., Gitler, A. D., Cashikar, A., Haynes, C. M., Hill, K. J., Bhullar, B., et al. (2006). α-Synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson’s models. Science, 313, 324–328.
Gitler, A. D., Bevis, B. J., Shorter, J., Strathearn, K. E., Hamamichi, S., Su, L. J., et al. (2008). The Parkinson’s disease protein α-synuclein disrupts cellular Rab homeostasis. Proceedings of the National Academy of Sciences of the United States of America, 105, 145–150.
Nemani, V. M., Lu, W., Berge, V., Nakamura, K., Onoa, B., Lee, M. K., et al. (2010). Increased expression of α-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron, 65, 66–79.
Toxic Oligomers
Cremades, N., Cohen, S. I. A., Deas, E., Abramov, A. Y., Chen, A. Y., Orte, A., et al. (2012). Direct observation of the interconversion of normal and toxic forms of α-synuclein. Cell, 149, 1048–1059.
Winner, B., Jappelli, R., Maji, S. K., Desplats, P. A., Boyer, L., Aigner, S., et al. (2011). In vivo demonstration that α-synuclein oligomers are toxic. Proceedings of the National Academy of Sciences of the United States of America, 108, 4194–4199.
LRRK2 Structure, Function and Localization
Alegre-Abarrategui, J., Christian, H., Lufino, M. M. P., Mutihac, R., Venda, L. L., Ansorge, O., et al. (2009). LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Human Molecular Genetics, 18, 4022–4034.
Beilina, A., Rudenko, I. N., Kaganovich, A., Civiero, L., Chau, H., Kalia, S. K., et al. (2014). Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson’s disease. Proceedings of the National Academy of Sciences of the United States of America, 111, 2626–2631.
Biskup, S., Moore, D. J., Celsi, F., Higashi, S., West, A. B., Andrabi, S. A., et al. (2006). Localization of LRRK2 to membranes and vesicular structures in mammalian brain. Annals of Neurology, 60, 557–569.
Mata, I. F., Wedemeyer, W. J., Farrer, M. J., Taylor, J. P., & Gallo, K. A. (2006). LRRK2 in Parkinson’s disease: Protein domains and functional insights. Trends in Neurosciences, 29, 286–293.
Paisán-Ruiz, C., Jain, S., Evans, E. W., Gilks, W. P., Simón, J., van der Brug, M., et al. (2004). Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron, 44, 595–600.
Piccoli, G., Condliffe, S. B., Bauer, M., Giesert, F., Boldt, K., De Astis, S., et al. (2011). LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool. The Journal of Neuroscience, 31, 2225–2237.
Zinprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., et al. (2004). Mutations in LRRK2 cause autosomal-dominant Parkinsonism with pleomorphic pathology. Neuron, 44, 601–607.
LRRK2 and Chaperone-Mediated Autophagy
Cuervo, A. M., & Dice, J. F. (1996). A receptor for the selective uptake and degradation of protein by lysosomes. Science, 273, 501–503.
Nichols, R. J., Dzamko, N., Morrice, N. A., Campbell, D. G., Deak, M., Ordureau, A., et al. (2010). 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson’s disease-associated mutations and regulates cytoplasmic localization. The Biochemical Journal, 430, 393–404.
Orenstein, S. J., Kuo, S. H., Tasset, I., Arias, E., Koga, H., Fernandez-Carasa, I., et al. (2013). Interplay of LRRK2 with chaperone-mediated autophagy. Nature Neuroscience, 16, 394–406.
Tong, Y., Yamaguchi, H., Giaime, E., Boyle, S., Kopan, R., Kelleher, R. J., III, et al. (2010). Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of α-synuclein, and apoptotic cell death in aged mice. Proceedings of the National Academy of Sciences of the United States of America, 107, 9879–9884.
Yang, Q., She, H., Gearing, M., Colla, E., Lee, M., Shacka, J. J., et al. (2009). Regulation of neuronal survival factor MEF2D by chaperonemediated autophagy. Science, 323, 124–127.
The PINK1-Parkin Pathway
Chen, Y., & Dorn, G. W., II. (2013). PINK1-phosphorylated mitofusin 2 is a parkin receptor for culling damaged mitochondria. Science, 340, 471–475.
Clark, I. E., Dodson, M. W., Jiang, C., Cao, J. H., Huh, J. R., Seol, J. H., et al. (2006). Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature, 441, 1162–1166.
Greene, A. W., Grenier, K., Aguileta, M. A., Muise, S., Farazifard, R., Haque, M. E., et al. (2012). Mitochondrial processing peptidase regulates PINK1 processing, import and parkin recruitment. EMBO Reports, 13, 378–385.
Jin, S. M., Lazarou, M., Wang, C., Kane, L. A., Narendra, D. P., & Youle, R. J. (2010). Mitochondrial membrane potential regulates PINK1 import and proteolytic destabilization by PARL. The Journal of Cell Biology, 191, 933–942.
Kazlauskaite, A., Kondapalli, C., Gourlay, R., Campbell, D. G., Ritorto, M. S., Hoffman, K., et al. (2014). Parkin is activated by PINK1-dependent phosphorylation of ubiquitin at Ser. The Biochemical Journal, 460, 127–139.
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., et al. (1998). Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature, 392, 605–608.
Lazarou, M., Jin, S. M., Kane, L. A., & Youle, R. J. (2012). Role of PINK1 binding to the TOM complex and alternate intracellular membranes in recruitment and activation of the E3 ligase parkin. Developmental Cell, 22, 320–333.
Narendra, D., Tanaka, A., Suen, D. F., & Youle, R. J. (2008). Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. The Journal of Cell Biology, 183, 795–803.
Park, J., Lee, S. B., Lee, S., Kim, Y., Song, S., Kim, S., et al. (2006). Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature, 441, 1157–1161.
Poole, A. C., Thomas, R. E., Andrews, L. A., McBride, H. M., Whitworth, A. J., & Pallanck, L. J. (2008). The PINK1/parkin pathway regulates mitochondrial morphology. Proceedings of the National Academy of Sciences of the United States of America, 105, 1638–1643.
Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M., Harvey, K., Gispert, S., et al. (2004). Hereditary early-onset Parkinson’s disease caused by mutations in PINK1. Science, 304, 1158–1160.
Vives-Bauza, C., Zhou, C., Huang, Y., Cui, M., de Vries, R. L. A., Kim, J., et al. (2010). PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proceedings of the National Academy of Sciences of the United States of America, 107, 378–383.
Parkin’s UPS/Mitophagic Actions
Chan, N. C., Salazar, A. M., Pham, A. H., Sweredoski, M. J., Kolawa, N. J., Graham, R. L. J., et al. (2011). Broad activation of the ubiquitin-proteasome system by Parkin is critical for mitophagy. Human Molecular Genetics, 20, 1726–1737.
Misko, A., Jiang, S., Wegorzewska, I., Milbrandt, J., & Baloh, R. H. (2010). Mitofusion 2 is necessary for transport of axonal mitochondria and interacts with the Miro/Milton complex. The Journal of Neuroscience, 30, 4232–4240.
Wang, X., Winter, D., Ashrafi, G., Schlehe, J., Wong, Y. L., Selkoe, D., et al. (2011). PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility. Cell, 147, 893–906.
Yoshii, S. R., Kishi, C., Ishihara, N., & Mizushima, N. (2011). Parkin mediates proteasome-dependent protein degradation and rupture of the outer mitochondrial membrane. The Journal of Biological Chemistry, 286, 19630–19640.
Ziviani, E., Tao, R. N., & Whitworth, A. J. (2010). Drosophila parkin requires PINK1 for mitochondrial translocation and ubiquitinates mitofusions. Proceedings of the National Academy of Sciences of the United States of America, 107, 5018–5023.
Neuroprotective Actions Independent of Mitophagy
Lee, Y., Karuppagounder, S. S., Shin, J. H., Lee, Y. I., Ko, H. S., Swing, D., et al. (2013). Parthanatos mediates AIMP2 activated age dependent dopaminergic neuronal loss. Nature Neuroscience, 16, 1392–1400.
McLelland, G. L., Soubannier, V., Chen, C. X., McBride, H. M., & Fon, E. A. (2014). Parkin and PINK1 function in a vesicular trafficking pathway regulating mitochondrial quality control. The EMBO Journal, 33, 282–295.
Müller-Rischart, A. K., Pilsl, A., Beaudette, P., Patra, M., Hadian, K., Funke, M., et al. (2013). The E3 ligase parkin maintains mitochondrial integrity by increasing linear ubiquitination of NEMO. Molecular Cell, 49, 908–921.
Shin, J. H., Ko, H. S., Kang, H., Lee, Y., Lee, Y. I., Pletinkova, O., et al. (2011). PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson’s disease. Cell, 144, 689–702.
DJ-1 Mutations and Oxidation
Blackinton, J., Lakshminarasimhan, M., Thomas, K. J., Ahmad, R., Greggio, E., Raza, A. S., et al. (2009). Formation of a stabilized cysteine sulfinic acid is critical for the mitochondrial function of the parkinsonism protein DJ-1. The Journal of Biological Chemistry, 284, 6476–6485.
Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O., Breedveld, G. J., Krieger, E., et al. (2003). Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science, 299, 256–259.
Canet-Avilés, R. M., Wilson, M. A., Miller, D. W., Ahmad, R., McLendon, C., Bandyopadhyay, S., et al. (2004). The Parkinson’s disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proceedings of the National Academy of Sciences of the United States of America, 101, 9103–9108.
Irrcher, I., Aleyasin, H., Seifert, E. L., Hewitt, S. J., Chhabra, S., Phillips, M., et al. (2010). Loss of the Parkinson’s disease-linked gene DJ-1 perturbs mitochondrial dynamics. Human Molecular Genetics, 19, 3734–3746.
Krebiehl, G., Ruckerbauer, S., Burbulla, L. F., Kieper, N., Maurer, B., Waak, J., et al. (2010). Reduced basal autophagy and impaired mitochondrial dynamics due to loss of Parkinson’s disease-associated protein DJ-1. PLoS ONE, 5, e9367.
Raturi, A., & Simmen, T. (2013). Where the endoplasmic reticulum and the mitochondrion tie the knot: The mitochondrial-associated membrane. Biochimica et Biophysica Acta, 1833, 213–224.
Thomas, K. J., McCoy, M. K., Blackinton, J., Beilina, A., van der Brug, M., Sandebring, A., et al. (2011). DJ-1 acts in parallel to the PINK1/parkin pathway to control mitochondrial function and autophagy. Human Molecular Genetics, 20, 40–50.
Emerging Genetic Risk Factors
Burchell, V. S., Nelson, D. E., Sanchez-Martinez, A., Delgado-Camprubi, M., Ivatt, R. M., Pogson, J. H., et al. (2013). The Parkinson’s disease genes Fbxo7 and parkin interact to mediate mitophagy. Nature Neuroscience, 16, 1257–1265.
Cullen, V., Sardi, S. P., Ng, J., Xu, Y. H., Sun, Y., Tomlinson, J. J., et al. (2011). Acid β-glucosidase mutants linked to Gaucher disease, Parkinson’s disease, and Lewy body dementia alter α-synuclein processing. Annals of Neurology, 69, 940–953.
Dehay, B., Ramirez, A., Martinez-Vicente, M., Perier, C., Canron, M. H., Doudnikoff, E., et al. (2012). Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America, 109, 9611–9616.
Gitler, A. D., Chesi, A., Geddie, M. L., Strathearn, K. E., Hamamichi, S., Hill, K. J., et al. (2009). α-Synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nature Genetics, 41, 308–315.
Gregory, A., Westaway, S. K., Holm, I. E., Kotzbauer, P. T., Hogarth, P., Sonek, S., et al. (2008). Neurodegeneration associated with genetic defects in phospholipase A. Neurology, 71, 1402–1409.
Kabuta, T., Furuta, A., Aoki, S., Furuta, K., & Wada, K. (2008). Aberrant interaction between Parkinson disease-associated mutant UCH-L1 and the lysosomal receptor for chaperone-mediated autophagy. The Journal of Biological Chemistry, 283, 23731–23738.
Kong, S. M. Y., Chan, B. K. K., Park, J. S., Hill, K. J., Aitken, J. B., Cottle, L., et al. (2014). Parkinson’s disease-linked human PARK9/ATP13A2 maintains zinc homeostasis and promotes α-synuclein externalization via exosomes. Human Molecular Genetics, 23, 2816–2833.
Mazzulli, J. R., Xu, Y. H., Sun, Y., Knight, A. L., Mclean, P. J., Caldwell, G. A., et al. (2011). Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell, 146, 37–52.
Morgan, N. V., Westaway, S. K., Morton, J. E. V., Gregory, A., Gissen, P., Sonek, S., et al. (2006). PLA2G6, encoding a phospholipase A, is mutated in neurodegenerative disorders with high brain iron. Nature Genetics, 7, 752–754.
Park, J. S., Koentjoro, B., Velvers, D., Mackay-Sim, A., & Sue, C. M. (2014). Parkinson’s disease-associated human ATP13A2 (PARK9) deficiency causes zinc dyshomeostasis and mitochondrial dysfunction. Human Molecular Genetics, 23, 2802–2815.
Plum-Favreau, H., Klupsch, K., Moisoi, N., Gandhi, S., Kjaer, S., Frith, D., et al. (2007). The mitochondrial protease HtrA2 is regulated by Parkinson’s disease-associated kinase PINK1. Nature Cell Biology, 9, 1243–1252.
Whitworth, A. J., Lee, J. R., Ho, V. M. W., Flick, R., Chowdhury, R., & McQuibban, G. A. (2008). Rhomboid-7 and HtrA2/Omi act in a common pathway with the Parkinson’s disease factors PINK1 and parkin. Disease Models & Mechanisms, 1, 168–174.
Nitric Oxide Signaling Discovered
Arnold, W. P., Mittal, C. K., Katsuki, S., & Murad, F. (1977). Nitric oxide activates guanylate cyclase and increases guanosine 3′:5′-cyclic monophosphate levels in various tissue preparations. Proceedings of the National Academy of Sciences of the United States of America, 74, 3203–3207.
Furchgott, R. F., & Zawadzki, J. V. (1980). The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature, 288, 373–376.
Garthwaite, J., Chalres, S. L., & Chess-Williams, R. (1988). Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain. Nature, 336, 385–388.
Ignarro, L. J., Buga, G. M., Wood, K. S., Byrns, R. E., & Chaudhuri, G. (1987). Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proceedings of the National Academy of Sciences of the United States of America, 84, 9265–9269.
Palmer, R. M. J., Ashton, D. S., & Moncada, S. (1988). Vascular endothelial cells synthesize nitric oxide from l-arginine. Nature, 333, 664–666.
Palmer, R. M., Ferrige, A. G., & Moncada, S. (1987). Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature, 327, 524–526.
Neuroprotective and Neurodestructive Actions of Nitric Oxide and Other Stress Factors
Chung, K. K. K., Thomas, B., Li, X., Pletnikova, O., Troncoso, J. C., Marsh, L., et al. (2004). S-nitrosylation of parkin regulates ubiquitination and compromises parkin’s protective function. Science, 304, 1328–1331.
LaVoie, M. J., Ostaszewski, B. L., Weihofen, A., Schlossmacher, M. G., & Selkoe, D. J. (2005). Dopamine covalently modifies and functionally inactivates parkin. Nature Medicine, 11, 1214–1221.
Lipton, S. A., Choi, Y. B., Pan, Z. H., Lei, S. Z., Chen, H. S. V., Sucher, N. J., et al. (1993). A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature, 364, 626–632.
Mosharov, E. V., Larsen, K. E., Kanter, E., Phillips, K. A., Wilson, K., Schmitz, Y., et al. (2009). Interplay between cytosolic dopamine, calcium, and α-synuclein causes selective death of substantia nigra neurons. Neuron, 62, 218–229.
Palacino, J. J., Sagi, D., Goldberg, M. S., Krauss, S., Motz, C., Wacker, M., et al. (2004). Mitochondrial dysfunction and oxidative damage in parkindeficient mice. The Journal of Biological Chemistry, 279, 18614–18622.
Uehara, T., Nakamura, T., Yao, D., Shi, Z. Q., Gu, Z., Ma, Y., et al. (2006). S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration. Nature, 441, 513–517.
Yao, D., Gu, Z., Nakamura, T., Shi, Z. Q., Ma, Y., Gaston, B., et al. (2004). Nitrosative stress linked to sporadic Parkinson’s disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. Proceedings of the National Academy of Sciences of the United States of America, 101, 10810–10814.
Chronic Inflammation and iNOS
Gao, H. M., Jiang, J., Wilson, B., Zhang, W., Hong, J. S., & Liu, B. (2002). Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: Relevance to Parkinson’s disease. Journal of Neurochemistry, 81, 1285–1297.
Lee, H. J., Suk, J. E., Patrick, C., Bae, E. J., Cho, J. H., Rho, S., et al. (2010). Direct transfer of α-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. The Journal of Biological Chemistry, 285, 9262–9272.
Liberatore, G. T., Jackson-Lewis, V., Vukosavic, S., Mandir, A. S., Vila, M., McAuliffe, W. G., et al. (1999). Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nature Medicine, 5, 1403–1409.
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988). Reactive microglia and positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology, 38, 1285–1291.
Zhang, W., Wang, T., Pei, Z., Miller, D. S., Wu, Z., Block, M. L., et al. (2005). Aggregated α-synuclein activated microglia: A process leading to disease progression in Parkinson’s disease. The FASEB Journal, 19, 533–542.
Exosomes and Cell-to-Cell Spread
Desplats, P., Lee, H. J., Bae, E. J., Patrick, C., Rockenstein, E., Crews, L., et al. (2009). Inclusion formation and neuronal cell death through neuronto-neuron transmission of α-synuclein. Proceedings of the National Academy of Sciences of the United States of America, 106, 13010–13015.
Emmanouilidou, E., Melachroinou, K., Roumeliotis, T., Garbis, S. D., Ntzouni, M., Marqaritis, L. H., et al. (2010). Cell-produced α-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. The Journal of Neuroscience, 30, 6838–6851.
Hansen, C., Angot, E., Bergström, A. L., Steiner, J. A., Pieri, L., Paul, G., et al. (2011). α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. The Journal of Clinical Investigation, 121, 715–725.
Harding, C., Hauser, J., & Stahl, P. (1983). Receptor-mediated endosytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. The Journal of Cell Biology, 97, 329–339.
Luk, K. C., Kehm, V. M., Zhang, B., O’Brien, P., Trojanowski, J. Q., & Lee, V. M. Y. (2011). Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. The Journal of Experimental Medicine, 209, 975–986.
Pan, B. T., & Johnstone, R. M. (1983). Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: Selective externalization of the receptor. Cell, 33, 967–978.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Beckerman, M. (2015). Parkinson’s Disease. In: Fundamentals of Neurodegeneration and Protein Misfolding Disorders. Biological and Medical Physics, Biomedical Engineering. Springer, Cham. https://doi.org/10.1007/978-3-319-22117-5_9
Download citation
DOI: https://doi.org/10.1007/978-3-319-22117-5_9
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-22116-8
Online ISBN: 978-3-319-22117-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)